Cassava Sciences Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while JPMorgan Equity Premium Income ETF trades at $57.85. The key difference: JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | JEPI | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $59.88 |
52-Week Low | $0.87 | $55.29 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
JEPI trades at $57.8, up 0.28% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating income through covered calls, offering monthly dividends, but key valuation ratios are not publicly disclosed. Recent news highlights its popularity among retirees for yield, though some articles note underperformance versus peers.
Outlook is mixed: strong income appeal supports demand, but competition and potential tax inefficiencies pose risks. Investors should weigh the high yield against total return lag and market volatility exposure. The bullish technical trend may face resistance near current levels if overbought conditions persist.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →